Testabol Depot
Overview
Testabol Depot British Dragon delivers testosterone cypionate at 250 mg/ml in a 10 ml multidose vial — 2,500 mg total per vial, covering a complete 5-week 500 mg/week cycle or a 10-week 250 mg/week TRT-equivalent base. Testosterone cypionate is a long-acting testosterone ester with an approximately 8-day half-life, producing stable plasma testosterone levels on twice-weekly injections and requiring no daily or every-other-day dosing. It is the most widely used injectable testosterone base in North American performance and clinical protocols and remains the standard first-cycle and stacking base for athletes across all experience levels. As a pure testosterone, Testabol Depot BD provides the full spectrum of androgenic and anabolic activity with a well-understood side effect profile that is manageable with standard on-cycle support. Steroid Warehouse carries the full British Dragon testosterone range including Testabol Enanthate and Testabol Propionate for users who require a different ester format.
About the Compound
Testosterone cypionate is testosterone with a cypionate ester attached at the C17-beta hydroxyl position. The ester slows release from the injection site oil depot into systemic circulation, extending the active half-life to approximately 8 days compared to a few hours for unesterified testosterone suspension. Once in circulation, esterases cleave the cypionate chain, releasing free testosterone identical to endogenous testosterone in every subsequent step: receptor binding, aromatization to estradiol, 5-alpha reduction to DHT, and HPG axis feedback.
The cypionate ester is marginally longer-acting than testosterone enanthate (~8 days vs ~7 days), which is historically why it became the preferred ester in North American clinical testosterone prescriptions while enanthate became the European standard. In practical terms, these two esters are pharmacologically interchangeable at equal doses with no meaningful performance or physiological difference. The choice between Testabol Depot BD and Testabol Enanthate BD comes down to user preference, not clinical distinction.
What It Does
- Drives muscle protein synthesis and nitrogen retention via androgen receptor binding: Testosterone binds the androgen receptor (AR) in skeletal muscle, triggering transcriptional programs that upregulate muscle protein synthesis rates, reduce protein catabolism, and increase nitrogen retention. Supraphysiological testosterone levels amplify these effects proportionally with dose, producing the accelerated lean mass accrual and recovery capacity that form the core of its use in performance protocols.
- Upregulates IGF-1 and satellite cell activation: Testosterone elevates circulating and local IGF-1 production, which activates muscle satellite cells and promotes hypertrophic signaling through PI3K/Akt/mTOR pathways. This amplifies the anabolic response to training beyond what AR binding alone produces, contributing to the synergistic muscle-building effect that makes testosterone uniquely effective compared to more selective anabolic compounds.
- Aromatizes to estradiol — necessary but requires management: A significant fraction of exogenous testosterone undergoes aromatization to estradiol (E2) via aromatase in adipose, liver, and muscle tissue. At supraphysiological testosterone doses, E2 rises proportionally. Well-managed E2 through aromatase inhibition with Anastrozole BD supports libido, bone density, joint health, and cardiovascular function. Unmanaged E2 elevation leads to water retention, gynecomastia, and blood pressure issues.
- Stimulates erythropoiesis via EPO upregulation: Testosterone stimulates renal erythropoietin (EPO) production, increasing red blood cell count, hemoglobin, and hematocrit. This improves oxygen-carrying capacity and training endurance. At higher doses or on longer cycles, hematocrit can rise to levels requiring monitoring and management to avoid cardiovascular risk from blood viscosity increases.
- Suppresses HPG axis — endogenous testosterone production stops: Exogenous testosterone provides strong negative feedback to the hypothalamus and pituitary, suppressing GnRH, LH, and FSH secretion. Leydig cell testosterone synthesis shuts down within 1–2 weeks of initiation. Testicular volume may decrease on long cycles. Full HPG axis recovery requires a properly structured PCT course after the cycle ends.
Who It's For
Testabol Depot BD is the starting point for first injectable AAS cycles, the base compound in virtually every multi-drug stack, and the preferred TRT-equivalent for cruise phases between heavier protocols. It suits any experience level and any goal — bulking, recomposition, or strength-focused training — because the dose and combination partners determine the outcome, not the compound itself. Testosterone cypionate at 250–500 mg/week with AI support and a structured PCT is the most evidence-supported, well-characterised injectable AAS protocol available.
The defining differentiator from Testabol Enanthate BD is ester length only: cypionate runs approximately one day longer per half-life cycle than enanthate. In practice, both esters produce the same steady-state testosterone exposure on twice-weekly dosing, the same AI requirements, and the same PCT timing. The two are clinically interchangeable. Users who have previously used testosterone enanthate can switch to cypionate at the same dose and frequency with no protocol adjustment required.
Users better served by a different testosterone format: those who want to adjust cycle timing rapidly should use Testabol Propionate BD, where the shorter ester allows faster blood level changes and a shorter wait before PCT. Users who want a blend with fast-onset short-ester coverage alongside long-ester stability may prefer Sustabol 350 BD. Users beginning their first AAS cycle should start with testosterone-only at 300–500 mg/week before adding any secondary compounds — this establishes personal AI requirements and recovery profile before stacking.
Testabol Depot vs Alternatives
| Compound | Key Differences | Choose Testabol Depot BD When | Choose Alternative When |
|---|---|---|---|
| Cypionat 250 Dragon Pharma (testosterone cypionate 250 mg/ml) | Identical active compound (testosterone cypionate 250 mg/ml); same half-life, dosing frequency, AI requirements, and PCT protocol; different brand and manufacturing source; no pharmacological distinction between the two products | British Dragon brand preferred; BD-sourced product desired for consistency with other BD compounds in the stack | Dragon Pharma brand preferred or more readily available; no clinical reason to prefer one testosterone cypionate source over another |
| Enantat 250 Dragon Pharma (testosterone enanthate 250 mg/ml) | Virtually identical pharmacological profile; enanthate half-life ~7 days vs cypionate ~8 days; both run on twice-weekly injection schedules; same aromatization rate, same AI requirements, same muscle-building effect at equal doses; the ~1-day half-life difference has no practical significance in steady-state use; traditional European ester vs North American ester distinction | Cypionate format specifically preferred; consistency with prior cypionate use; no clinical advantage of either ester over the other | Enanthate format preferred; prior cycle history is with enanthate and no reason to change; both deliver identical outcomes at equal doses |
| Sustanon 270 Dragon Pharma (testosterone blend 270 mg/ml) | Multi-ester blend combining propionate, phenylpropionate, isocaproate, and decanoate; initial fast-onset peak from short esters followed by sustained release from long esters; slightly less stable blood levels than single-ester cypionate on twice-weekly dosing; more complex ester clearance makes PCT timing slightly less predictable than single-ester protocols | Clean single-ester pharmacokinetics preferred; predictable half-life and defined PCT start timing (14–21 days post last injection); stable blood levels without multi-ester fluctuation | Multi-ester blend preferred for faster initial onset; user has a specific preference for Sustanon-style protocols from prior experience |
Combinations
| Goal | Primary | Support Compounds | Notes |
|---|---|---|---|
| Classic bulk — mass and strength | Testabol Depot BD 500 mg/wk (wks 1–16) | Methanabol Tablets BD 30–40 mg/day (wks 1–4 kickstart) + Anastrozole BD | Methanabol (Dianabol) kickstart fills the gap while cypionate reaches peak blood levels over the first 2–3 weeks; high oral aromatization in weeks 1–4 means AI dose often needs to be higher during the kickstart phase and then recalibrated downward once the oral is dropped; confirm E2 bloodwork at week 4 after removing Methanabol to reset Anastrozole dose for the remainder of the cycle |
| Lean mass — recomposition and vascularity | Testabol Depot BD 400 mg/wk (wks 1–16) | Boldabol 200 BD (boldenone undecylenate) 400 mg/wk + Anastrozole BD | Boldenone adds lean mass accrual, enhanced vascularity, and EPO-mediated hematocrit increase alongside testosterone; low aromatization rate of boldenone means total E2 load per mg is lower than testosterone-only protocols, but hematocrit requires careful monitoring and may require blood donation; Boldabol 200 has a very long half-life (>14 days) — plan for 16-week minimum cycle length and 3+ weeks post-last-injection before PCT |
| Intermediate bulk — mass with joint support | Testabol Depot BD 500 mg/wk (wks 1–14) | Decabol 250 BD (nandrolone decanoate) 300–400 mg/wk + Anastrozole BD + Caberlin (cabergoline) on standby | The classic testosterone + nandrolone bulk; nandrolone adds collagen synthesis support and joint lubrication that makes this stack effective for heavy compound training; run testosterone:nandrolone at minimum 2:1 ratio; nandrolone can raise prolactin — have cabergoline (0.25 mg twice weekly) available and introduce if mid-cycle prolactin bloodwork shows elevation above range |
| Cutting — strength preservation and hardening | Testabol Depot BD 300–400 mg/wk (wks 1–12) | Mastabol 100 BD (masteron propionate) 400 mg/wk + Stanabol 50 Inj BD 50 mg/day (final 6 wks) | Masteron reduces water retention and improves muscle density through anti-estrogenic activity at tissue level; injectable Winstrol (Stanabol 50 Inj) added in the final 6 weeks for hardening and strength retention; best run at a caloric deficit; monitor lipids closely — Winstrol significantly suppresses HDL and the combination of three compounds amplifies the lipid burden; omega-3 3–4 g/day throughout |
Side Effects & Management
| Side Effect | Frequency | How to Handle It |
|---|---|---|
| Water retention and bloating | Common — E2-driven; more pronounced at doses above 400 mg/week without AI | Primary management: Anastrozole BD 0.5 mg every other day starting week 1; titrate based on E2 bloodwork (target 20–40 pg/mL on cycle); do not over-suppress E2 — joint pain, low libido, and depression indicate E2 is too low; water retention that persists despite controlled E2 may be sodium-driven, not estrogen-driven |
| Gynecomastia | Uncommon with AI in place; risk rises significantly without AI or at doses above 500 mg/week | Prevention: Anastrozole BD from week 1; at first sign of nipple sensitivity or breast tissue tenderness add Tamoxifen BD 20–40 mg/day alongside the AI; if AI dose adjustment does not resolve early symptoms within 2 weeks, increase AI and maintain tamoxifen; Exemestane BD can substitute for Anastrozole in AI-resistant cases |
| Acne and oily skin | Common — dose-dependent; driven by DHT and sebaceous gland androgen receptor activity | Topical cleansing routines; Accutane (isotretinoin) for severe cystic cases; body acne (back, shoulders, chest) is particularly common with high-dose testosterone; oily skin typically resolves within weeks of cycle end; finasteride reduces DHT conversion and may reduce androgen-sensitive acne in genetically predisposed users |
| Androgenic alopecia (male pattern baldness) | Genetically predisposed users only — accelerated by DHT elevation from testosterone conversion | Testosterone converts to DHT via 5-alpha reductase; individuals predisposed to MPB experience acceleration on cycle; Finasteride Dragon Pharma 1 mg/day reduces scalp DHT; finasteride is compatible with testosterone cycles without reducing anabolic efficacy — muscle tissue has minimal 5-alpha reductase activity, so DHT reduction in scalp does not meaningfully affect muscle-building response |
| Hematocrit elevation | Common — EPO-mediated; more pronounced at higher doses and on longer cycles | Monitor hematocrit every 6–8 weeks; target below 52%; at 52–54%: increase hydration, consider blood donation (250–500 ml); above 54%: reduce testosterone dose and review cycle length; Ecosprin 75 mg/day as antiplatelet support when hematocrit is elevated; elevated hematocrit is the primary cardiovascular risk from AAS use — hyperviscosity-related thrombosis does not announce itself with symptoms before it becomes serious |
| Blood pressure elevation | Common at higher doses; driven by water retention (E2), hematocrit increase, and direct vascular effects | Control E2 with Anastrozole BD; monitor hematocrit; measure blood pressure weekly; target below 130/80 mmHg on cycle; if elevated despite E2 control: Amlip (amlodipine) 5 mg/day; Ecosprin 75 mg/day for cardiovascular protection throughout the cycle |
| HDL suppression & lipid disruption | Common — injectable testosterone has moderate lipid impact; significantly worsened if combined with oral AAS | Pre-cycle lipid panel as baseline; mid-cycle check at week 6–8; omega-3 fatty acids 3–4 g/day throughout; maintain cardiovascular training; avoid combining with highly lipid-toxic orals (Winstrol, Halotestin) without concurrent monitoring; lipids typically recover within 4–8 weeks post-cycle |
| Hepatotoxicity (when combined with oral AAS) | Injectable testosterone alone is not hepatotoxic; relevant when oral AAS are added to the stack | Testosterone cypionate itself does not stress the liver; hepatotoxicity risk arises from concurrent oral AAS; when orals are in the stack, add Liv.52 Herbal Liver Support and monitor ALT/AST; limit oral AAS phases to 4–6 weeks maximum |
Bloodwork Monitoring
| Lab | When to Test | Target & Action Threshold |
|---|---|---|
| Estradiol (E2) | Baseline; week 4 (first AI dose adjustment); week 8–10; post-cycle | Target on cycle: 20–40 pg/mL; above 50 pg/mL with water retention or gynecomastia signs: increase Anastrozole BD dose; below 15 pg/mL with joint pain, low libido, depressed mood: reduce AI dose; E2 management is the most active monitoring variable throughout the cycle |
| Total testosterone | Baseline (pre-cycle); week 6–8 (mid-cycle); post-PCT (4 weeks after completion) | Mid-cycle total testosterone on 500 mg/week is typically 2,000–5,000 ng/dL — use this reading primarily to confirm product is dosed as labeled; post-PCT target: return to pre-cycle baseline; if post-PCT testosterone remains below 300 ng/dL at 6 weeks post-PCT, HPG recovery is incomplete |
| Hematocrit & CBC | Baseline; week 6; week 12 (if running 16-week cycle) | Keep hematocrit below 52%; hemoglobin below 17.5 g/dL; above threshold: hydration, blood donation, dose reduction; CBC also confirms platelet count and identifies any haematological abnormalities before they become symptomatic |
| Lipid panel (HDL, LDL, TG) | Baseline; week 6–8; post-cycle (6 weeks after) | HDL should remain above 40 mg/dL; LDL below 130 mg/dL; TG below 150 mg/dL; injectable testosterone alone has moderate lipid impact; significantly worsened with oral AAS co-administration; omega-3 supplementation and continued cardiovascular training are the primary management tools |
| Blood pressure | Baseline; weekly self-monitoring during cycle | Target below 130/80 mmHg on cycle; above 140/90 mmHg: review E2 control and hematocrit first; add Amlip (amlodipine) if BP persists above target despite optimised AI and normal hematocrit; Ecosprin 75 mg daily for cardiovascular protection throughout |
| LH + FSH | Baseline (pre-cycle); post-PCT (4 weeks after completing PCT) | Baseline confirms normal pre-cycle pituitary function; post-PCT LH and FSH should return to pre-cycle range; persistently suppressed LH/FSH at 4 weeks post-PCT indicates incomplete HPG recovery — continue SERM therapy for a further 2 weeks and retest |
| ALT & AST (liver) | Baseline; mid-cycle if using concurrent oral AAS | Injectable testosterone has minimal direct hepatotoxicity; liver enzymes relevant primarily when combining with hepatotoxic orals (Dianabol, Winstrol, Anadrol); ALT/AST above 3× upper normal limit: reduce or discontinue the hepatotoxic oral; add Liv.52 Herbal Liver Support for the duration of the oral phase |
PCT
Testosterone cypionate has an approximately 8-day half-life. After the last injection, it takes 3–4 half-lives (24–32 days) to fall below a level that meaningfully suppresses the HPG axis. Wait 14–21 days after the last injection before starting PCT — at 14 days, blood testosterone levels have fallen to approximately 25% of the post-injection peak; by 21 days, to approximately 12%. Starting SERM therapy before this window means the HPG axis is still under androgen suppression and the SERM cannot fully drive LH/FSH recovery.
Standard 4-week PCT protocol:
- Weeks 1–2: Tamoxifen BD 40 mg/day + Clomiphene BD 50 mg/day
- Weeks 3–4: Tamoxifen BD 20 mg/day + Clomiphene BD 25 mg/day
For cycles longer than 16 weeks or those run at ≥600 mg/week: Add an HCG blast before PCT. Run HCG 5,000 IU Dragon Pharma at 2,500 IU twice over 5 days, ending 2 days before the first SERM dose. HCG restimulates Leydig cells directly, reversing testicular atrophy and improving initial SERM responsiveness. Do not run HCG alongside SERMs — use them sequentially.
Confirm HPG recovery with bloodwork 4 weeks after completing PCT. Total testosterone should be at or above pre-cycle baseline. LH and FSH should be within normal range. If testosterone remains below 300 ng/dL, extend SERM therapy at 20 mg/day tamoxifen for a further 2 weeks and retest.
Practical Summary
- Inject E3.5D for stable blood levels: split the weekly dose into two equal injections 3.5 days apart (e.g. Monday morning + Thursday evening); this maintains steady plasma testosterone and avoids the mid-week trough common with once-weekly dosing; consistent injection timing makes AI dose titration more predictable.
- 500 mg/week = 1 ml × 2 per week: one 10 ml vial covers 5 weeks at 500 mg/week; plan vial supply before cycle start; do not reduce to a lower dose mid-cycle because of supply issues — maintain consistent dosing or do not start.
- AI from week 1 — do not wait for symptoms: Anastrozole BD 0.5 mg every other day from the first injection; adjust based on E2 bloodwork at week 4 — never by feel alone; both high and crashed E2 cause problems that are indistinguishable by symptoms without bloodwork.
- PCT start: 14–21 days after last pin: cypionate half-life ~8 days; wait minimum 14 days before first SERM dose; for long or heavy cycles, use the 21-day window and add an HCG blast in the intervening period.
- Pre-cycle bloodwork before the first injection: establish baseline testosterone, E2, hematocrit, lipids, and blood pressure before starting; mid-cycle check at week 6–8; post-PCT check 4 weeks after SERM completion; these three timepoints give a complete picture of cycle impact and recovery.
- First cycles — testosterone only: running testosterone alone for the first cycle establishes how you aromatize, what AI dose you need, and how you respond to suppression; add secondary compounds only from a second or later cycle once baseline AI requirements and recovery profile are known.
Testabol Depot British Dragon provides testosterone cypionate at 250 mg/ml in a 10 ml vial — 2,500 mg per vial, covering a complete 5-week 500 mg/week protocol or a 10-week 250 mg/week TRT-equivalent base. The cypionate ester's 8-day half-life delivers stable plasma testosterone on twice-weekly injections, keeping blood levels consistent and minimizing peaks and troughs. As the most versatile long-ester testosterone available, Testabol Depot BD serves equally as a standalone first cycle, a stacking base for mass or recomposition goals, or a cruise-phase testosterone between heavier protocols. steroidwarehouse.com carries the complete British Dragon testosterone range including enanthate and propionate variants.
References
| Source | Topic | Link |
|---|---|---|
| New England Journal of Medicine / PubMed | Bhasin S et al. 1996 — randomized controlled trial evaluating 600 mg/week testosterone enanthate in healthy men with and without resistance training; demonstrated significant increases in fat-free mass, muscle size, and strength, especially when supraphysiologic testosterone was combined with resistance training | Bhasin S, et al. (1996) ↗ |
| American Journal of Physiology-Endocrinology and Metabolism / PubMed | Bhasin S et al. 2001 — graded testosterone enanthate dose-response study using 25–600 mg/week for 20 weeks under GnRH suppression; demonstrated dose-dependent changes in fat-free mass, muscle size, strength, power, fat mass, hemoglobin, HDL cholesterol, and IGF-I | Bhasin S, et al. (2001) ↗ |
| New England Journal of Medicine / PubMed | Finkelstein JS et al. 2013 — randomized study separating testosterone and estradiol effects in men; showed that androgen deficiency accounted for decreases in lean mass, muscle size, and strength, estrogen deficiency primarily accounted for increases in body fat, and both contributed to sexual function changes | Finkelstein JS, et al. (2013) ↗ |
| NCBI Bookshelf / StatPearls | Anabolic steroids overview — clinical reference on anabolic-androgenic steroids including testosterone derivatives; covers androgen receptor mechanism, HPG-axis suppression, adverse effects, misuse patterns, and monitoring considerations | StatPearls: Anabolic Steroids ↗ |
| NCBI Bookshelf / Endotext | Androgen physiology and pharmacology — comprehensive overview of testosterone biosynthesis, androgen receptor signaling, HPG-axis regulation, aromatization, synthetic androgen pharmacology, and endocrine suppression from exogenous androgen use | Endotext: Androgen Physiology, Pharmacology, Use and Misuse ↗ |
What is Testabol Depot?
Testabol Depot is an injectable anabolic steroid (Testosterone Cypionate) for muscle growth; see What is Testabol Depot. It's potent—consult professionals for safe use.
What does Testabol Depot do?
It promotes muscle mass, strength, and performance; see What Does Testabol Depot Do. It enhances physique—monitor with labs.
How long does Testabol Depot stay in your system?
Detectable for up to 3 months; see How Long Does Testabol Depot Stay in Your System. Monitor with professional guidance.
How do I take Testabol Depot?
250-500 mg/week, split weekly or bi-weekly; see How to Take Testabol Depot. Start low—consult professionals for dosing.
How to cycle Testabol Depot?
10-12 weeks, 250-500 mg/week, PCT after 10-14 days; see How to Cycle Testabol Depot. Stack with testosterone—consult professionals for protocols.
What is Testabol Depot used for?
Testabol Depot is commonly associated with supporting testosterone levels, muscle development, strength gains, recovery, athletic performance, and overall anabolic activity.
What are the main benefits of Testabol Depot?
Commonly reported benefits include increased muscle mass, enhanced strength, improved recovery, better workout performance, support for lean body composition, and overall testosterone support.
What makes Testabol Depot different from shorter-acting testosterone products?
Testabol Depot is designed to provide a slower and more sustained release of testosterone, allowing for longer-lasting activity compared to shorter-acting testosterone esters.
Related Products
